摘要
类风湿关节炎(rheumatoid arthritis,RA)是一种严重的慢性全身性自身免疫性炎症疾病,致残率高,给患者及家属带来巨大的经济负担。已有的RA治疗药物随着临床应用范围的扩大,其不良反应如感染和癌症发生率增加等也逐渐暴露;而且部分患者对已有治疗药物无响应或不能持续响应。因此,RA治疗药物的开发一直是自身免疫疾病相关药物研究中的难点之一。本文主要针对治疗RA靶向细胞因子和免疫细胞的生物制剂、创新疗法的作用机制及研究进展作一综述,旨在为今后RA的治疗和药物研发提供思路。
Rheumatoid arthritis(RA)is a serious chronic systemic autoimmune inflammatory disease with high disability rate,which will bring huge economic burden to patients and their families.With the expansion of clinical application,the side effects of the current drugs,such as infection and cancer incidence,are gradually exposed.In addition,some patients have no response or no continuous response to the drugs.Therefore,the development of drugs against RA has been one of the obstacles in research of drugs against autoimmune-related diseases.This paper mainly reviews the action mechanism and research progresses of biological drugs targeting cytokines and immune cells and innovative therapies so as to provide ideas for the treatment of RA and drug development in the future.
作者
赵靖(综述)
潘祝平(审校)
ZHAO Jing;PAN Zhu-ping(Center for Drug Evaluation,National Medical Products Administration,Beijing 100022,China;不详)
出处
《中国生物制品学杂志》
CAS
CSCD
2020年第12期1460-1465,共6页
Chinese Journal of Biologicals
关键词
类风湿关节炎
抗风湿生物制剂
细胞因子
免疫细胞
先进疗法
Rheumatoid arthritis(RA)
Biological drugs against RA
Cytokine
Immune cells
Advanced therapy
